Novartis’ Historic CAR-T Approval, Gilead-Kite Megadeal, & FDA Crackdown on Stem Cell Hucksters

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.